Drug & supplement interaction

Delta-9-tetrahydrocannabinol (thc) + Rasagiline

Rasagiline brand name: Azilect.

No Known Interaction

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated July 2026 · Pair last verified Sep 13, 2026

The bottom line No known interaction

We found no known interaction between Delta-9-tetrahydrocannabinol (thc) and Rasagiline in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone taking this? Share

Facebook Post Reddit Email

On this page

Interaction report

Delta-9-tetrahydrocannabinol (thc) and Rasagiline

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Rasagiline and Delta-9-tetrahydrocannabinol (thc) in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.

If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Delta-9-tetrahydrocannabinol (thc) safety at a glance

Delta-9-tetrahydro... overall Use caution THC is psychoactive, can impair judgment and coordination, and its legal status varies; use only under medical supervision.

Pregnancy Unsafe When used orally or inhaled. Cannabinoid constituents in cannabis, such as THC, pass through the placenta and can reduce fetal growth and increase the risk for... Read the full pregnancy detail

Breastfeeding Likely Unsafe When used orally or inhaled. THC is concentrated and excreted in breast milk for longer than 6 weeks after cessation of use; prolonged use of cannabis containin... Read the full breastfeeding detail

Pregnancy & breastfeeding ratings are from Natural Medicines (Therapeutic Research Center) — the full detail is in the Special populations card below. Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Rasagiline and Delta-9-tetrahydrocannabinol (thc)? Ask Dr. Brian Staiger, PharmD, BCPS directly ›

How we checked

Why No Interaction Is Listed for Rasagiline

Interactions in our licensed database are recorded against drug classes, not just single drug names. Rasagiline is filed under 8 classifications — including monoamine oxidase inhibitors (maois), dopamine agonists, serotonergic drugs. Delta-9-tetrahydrocannabinol (thc) has documented interactions with 16 drug classes — the most serious being alcohol (ethanol) (moderate), anesthesia (moderate) and anticoagulant/antiplatelet drugs (moderate) — and none of Rasagiline’s classifications are among them.

Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.

Keep it in perspective

Delta-9-tetrahydrocannabinol (thc) Does Interact With Other Medications

Delta-9-tetrahydrocannabinol (thc) has 762 moderate, 336 minor known drug interactions in our database — Rasagiline isn’t one of them. If you take anything else, check it against the full list below.

Moderate 762 Minor 336 No known interaction 1,732 (incl. Rasagiline)

Taking anything else?

Check Another of Your Medications Against Delta-9-tetrahydrocannabinol (thc)

Covers the 2,830 medications we’ve checked against Delta-9-tetrahydrocannabinol (thc). Pick one to open its full report.

What to actually watch for

No Interaction Found — But Data Suggests Delta-9-tetrahydrocannabinol (thc) and Rasagiline May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so taking both can make those effects more likely to turn up, and harder to pin on one or the other if they do. 5 of them are worth acting on rather than waiting out — marked below.

Hallucinations Worth acting on Additional detail
Delta-9-tetrahydrocannabinol (thc)

“There is limited reliable information available about the adverse effects associated with pure THC. When inhaled or used orally, cannabis can cause various adverse effects, many of which are thought to be related to THC.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in arrhythmia.
“Cannabinoids such as THC can increase anxiety, confusion, depressed mood, and hallucinations, and reduce motivation. Cannabis dabbing, the making of a waxy product with extremely high concentrations of THC, is thought to increase the risk of anxiety, agitation, paranoia, and psychosis.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in anxiety.
6 sources cited

96384. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73. PubMed

110252. Murray CH, Glazer JE, Lee R, Nusslock R, de Wit H. ?9-THC reduces reward-related brain activity in healthy adults. Psychopharmacology (Berl) 2022;239(9):2829-2840. PubMed

110257. Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910. PubMed

108341. Mullins MF. Cannabis dabbing: An emerging trend. Nursing. 2021;51(5):46-50.

91914. Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product--Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771-2. PubMed

103796. Monte AA, K Shelton SK, Mills E., Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med. 2019 Apr 16;170(8):531-537. PubMed
Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Confusion Worth acting on Additional detail
Delta-9-tetrahydrocannabinol (thc)
“Meta-analyses of clinical and observational research involving adults with a mean age of at least 50 years show that increasing the dose of natural or synthetic THC in cannabinoid-based medicines is associated with a modest increase in overall adverse effects, including dizziness/light-headedness, mobility/balance/coordination difficulties, somnolence, disorientation, memory impairment, fatigue, and euphoria.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in cluster headache.
6 sources cited

105559. Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. PubMed

110257. Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910. PubMed

110249. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.

61759. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed

61764. Perras, C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg.Health Technol. 2005;(72):1-4.

61820. Rog, D. J., Nurmikko, T. J., and Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079.
Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Low mood Worth acting on Additional detail

Delta-9-tetrahydrocannabinol (thc)

Recorded for Delta-9-tetrahydrocannabinol (thc) in the same Natural Medicines adverse-effect record shown under Hallucinations above.

Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Raised blood pressure Worth acting on Additional detail
Delta-9-tetrahydrocannabinol (thc)
“Orally, edible cannabis products containing 50 mg or more of THC have been associated with myocardial infarction and ventricular arrhythmia. In a case report, a 2-year-old boy developed bradycardia with first-degree atrioventricular block which lasted 12 hours, after accidentally consuming an unknown number of cannabis gummies containing THC.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in arrhythmia.
6 sources cited

103796. Monte AA, K Shelton SK, Mills E., Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med. 2019 Apr 16;170(8):531-537. PubMed

110237. Idris I, Diez JR, Assoku BA, Beker S. Accidental ingestion of tetrahydrocannabinol-laced gummies causing bradycardia and first-degree atrioventricular block in a pediatric patient: A case report. Cureus 2022;14(7):e26826. PubMed

110258. Highlights of prescribing information. MARINOL (dronabinol) capsules, for oral use, CIII. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed April 10, 2023.

110259. Cesamet (nabilone) capsules for oral administration. May 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed April 10, 2023.

110231. Maharaj N, Swarath S, Seecheran R, Seecheran V, Seecheran NA. Suspected cannabis vaping-induced pericardial effusion. J Investig Med High Impact Case Rep 2022;10:23247096221140251. PubMed

61759. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed
Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
A higher chance of infection Worth acting on Additional detail
Delta-9-tetrahydrocannabinol (thc)
“Taking a prescription drug called dronabinol (Marinol), a synthetic form of THC, has been associated with hypersensitivity reactions, including lip swelling and oral lesions, skin hives, rash, or flushing, or throat tightness.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in urinary tract infections (utis).
2 sources cited

110258. Highlights of prescribing information. MARINOL (dronabinol) capsules, for oral use, CIII. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed April 10, 2023.

110257. Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910. PubMed
Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Sweating / Reduced appetite Additional detail

Delta-9-tetrahydrocannabinol (thc)

Recorded for Delta-9-tetrahydrocannabinol (thc) in the same Natural Medicines adverse-effect record shown under Hallucinations above.

Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Dry mouth Additional detail
Delta-9-tetrahydrocannabinol (thc)
“Meta-analyses of clinical and observational research involving adults with a mean age of at least 50 years shows that increasing the dose of natural or synthetic THC in cannabinoid-based medicines is associated with a modest increase in the rate of dry mouth, nausea, and vomiting. Dry mouth has also been reported in clinical research.”

Delta-9-tetrahydrocannabinol (thc) · Natural Medicines adverse-effect record, reported in cancer.
6 sources cited

105559. Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. PubMed

110257. Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910. PubMed

110249. Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.

110258. Highlights of prescribing information. MARINOL (dronabinol) capsules, for oral use, CIII. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed April 10, 2023.

110259. Cesamet (nabilone) capsules for oral administration. May 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed April 10, 2023.

61759. Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed
Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Low blood pressure Additional detail

Delta-9-tetrahydrocannabinol (thc)

Recorded for Delta-9-tetrahydrocannabinol (thc) in the same Natural Medicines adverse-effect record shown under Raised blood pressure above.

Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›
Drowsiness Additional detail

Delta-9-tetrahydrocannabinol (thc)

Recorded for Delta-9-tetrahydrocannabinol (thc) in the same Natural Medicines adverse-effect record shown under Hallucinations above.

Rasagiline

Listed in the ADVERSE REACTIONS section of the FDA label for Rasagiline. Read the label on DailyMed ›

Showing the 10 most notable of 21 shared effects — ranked by how unusual each one is, not just whether both lists mention it.

Reported for Delta-9-tetrahydrocannabinol (thc) but not commonly for Rasagiline: an irregular heartbeat, a heart attack, memory problems and a fast or pounding heartbeat.

Effects for Rasagiline come from the ADVERSE REACTIONS section of its FDA label; effects for Delta-9-tetrahydrocannabinol (thc) come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Special populations

Delta-9-tetrahydrocannabinol (thc) in Pregnancy & Breastfeeding

Pregnancy Unsafe

When used orally or inhaled. Cannabinoid constituents in cannabis, such as THC, pass through the placenta and can reduce fetal growth and increase the risk for preterm birth. Cannabis use during pregnancy is also associated with placental abruption, stillbirth, preterm delivery, fetal abnormalities, low birth weight, small for gestational age, increased need for neonatal intensive care, and childhood leukemia. Prenatal cannabis use has also been associated with long-term adverse developmental effects in the offspring, such as worsened cognition, increased risk for neurodevelopmental disorders such as autism spectrum disorder, and increased risk for psychological issues during adolescence. Due to the observational nature of these studies, it is unclear if cannabis causes these adverse effects. Umbilical artery Doppler scans also show that cannabis use can increase placental vascular resistance. Cannabis use during pregnancy has been associated with increased risk of anemia and hypertension in the mother. Although the safety of pure THC has not been investigated during pregnancy, it is likely that THC is at least partially responsible for these safety concerns. The rate of negative fetal outcomes due to cannabis use during pregnancy may have been previously underestimated due to reliance on maternal self-reporting of use. Recent programs requiring maternal urine toxicology testing have increased awareness of maternal cannabis use and suggest that negative fetal outcomes occur more frequently than previously recorded.

Lactation Likely Unsafe

When used orally or inhaled. THC is concentrated and excreted in breast milk for longer than 6 weeks after cessation of use; prolonged use of cannabis containing THC during lactation has been associated with delayed motor development. Observational research in mothers who successfully abstained from cannabis use for 6 weeks (confirmed by a negative THC urine screen) after smoking cannabis prenatally at least twice weekly, found that THC levels in breastmilk increased during the first 2 weeks of abstinence and then decreased but remained detectable at 6 weeks. For patients planning to breastfeed, recommend abstaining from THC use prenatally and during lactation. Recommendations to discard breastmilk until THC levels are undetectable are not practical, as this may take more than 6 weeks.

DISCLAIMER: This tool is intended for informational purposes only, and should not be interpreted as specific medical advice. Patients should consult with a qualified healthcare provider before making decisions about therapies and/or health conditions.© 2026 Therapeutic Research Center

Everything else you take

See Every Supplement That Interacts With Rasagiline

This page covers Delta-9-tetrahydrocannabinol (thc) only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Rasagiline page lists 173 supplements it has a documented interaction with, worst first, each one explained.

The most serious there right now: Activated Charcoal (major), Beer (major), Bitter Orange (major), Brewer's Yeast (major) and Cowhage (major).

By severity: 14 major · 125 moderate · 34 minor.

From our pharmacist’s overview on the Rasagiline page

“Rasagiline (Azilect) treats Parkinson's disease by blocking monoamine oxidase, the same enzyme that clears tyramine from aged and fermented foods. That shared pathway explains most of the 14 major-rated interactions on this page.”

Reviewed by 2 · Jul 18, 2026

Open the Rasagiline interaction page

How much people look this up

Where Delta-9-tetrahydrocannabinol (thc) and Rasagiline Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Delta-9-tetrahydrocannabinol (thc)

Top half

#518 of 1,452 supplements looked up here in the last 7 days

29 days ago today

Medication Rasagiline

Steady interest

#2,343 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?

Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Delta-9-tetrahydrocannabinol (thc) reference on this page ↓
Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Delta-9-tetrahydrocannabinol (thc) and Rasagiline records this page draws on were last updated July 11, 2026.
What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.

Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD, BCPS.

Supplement

About Delta-9-tetrahydrocannabinol (thc)

What is Delta-9-tetrahydrocannabinol (thc)?

Chronic or nerve pain
Nausea and vomiting from chemotherapy
Appetite loss and weight loss
Muscle spasticity
Sleep problems
Anxiety and stress

THC is the main mind-altering compound in cannabis and is best known for causing a 'high.' A prescription form (dronabinol) is approved for chemotherapy-related nausea and appetite loss, but for most other uses the evidence is mixed or limited, and THC can impair thinking and driving. It should be avoided in pregnancy and breastfeeding and used only with medical guidance.

Cannabis sativa · Cannabaceae · Flowering tops and resin of the cannabis plant (THC is a single cannabinoid isolated or concentrated from these) · Prescription oral capsules (dronabinol), oral oil/solution, dried flower, vape and concentrate products (such as butane hash oil/dabs), tinctures, and edibles

An interaction check asks whether these two react with each other — it does not ask whether Delta-9-tetrahydrocannabinol (thc) is a good idea for someone in your situation. Here is what our Delta-9-tetrahydrocannabinol (thc) record says about it on its own.

Delta-9-tetrahydrocannabinol (thc): dosing

There is no single standard dose of THC for general use, and the right amount varies widely from person to person based on tolerance, the product, and the reason for use. Concentrated products contain much more THC than dried flower, which makes accidental overuse easy.For prescription products such as dronabinol, a doctor sets the dose.

From our Delta-9-tetrahydrocannabinol (thc) monograph — the full record covers uses, side effects and every documented interaction.

Read the full Delta-9-tetrahydrocannabinol (thc) monograph & all interactions

Medication

About Rasagiline

What Is Rasagiline Used For?

Brand name: Azilect

Rasagiline tablets — sold as Azilect, Rasagiline, and Rasagiline mesylate — are approved to treat Parkinson's disease (PD). They can be used on their own (monotherapy) or added to other Parkinson's medications, including levodopa.

When used alongside levodopa, rasagiline helps manage Parkinson's symptoms that are not fully controlled by levodopa alone. Your doctor may adjust your levodopa dose when the two are combined.

Most-Reported Side Effects for Rasagiline

From FAERS, the FDA’s public side-effect reporting system (11,069 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.

Fall 1,066 reports

Hallucination 960 reports

Dyskinesia 765 reports

Dizziness 659 reports

Tremor 650 reports

See full Rasagiline drug information

Keep checking

Other Drugs & Delta-9-tetrahydrocannabinol (thc)

Browse every other medication we’ve checked against Delta-9-tetrahydrocannabinol (thc) — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major

762Moderate

336Minor

1,731No known interaction

762 Moderate 336 Minor 1,731 No interaction

Moderate

762 interactions

Showing 60 of 762 moderate interactions — see all 762 on the Delta-9-tetrahydrocannabinol (thc) page.

Minor

336 interactions

Showing 60 of 336 minor interactions — see all 336 on the Delta-9-tetrahydrocannabinol (thc) page.

No interaction 1,731 drugs checked — show the list

We also checked Delta-9-tetrahydrocannabinol (thc) against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 1,731 medications checked with no known interaction — see the full Delta-9-tetrahydrocannabinol (thc) list.

See the full Delta-9-tetrahydrocannabinol (thc) interactions page

See every supplement checked against Rasagiline, ranked by severity

Evidence & sources

Delta-9-tetrahydrocannabinol (thc) References

The 76 references that drive our Delta-9-tetrahydrocannabinol (thc) monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

Gruenwald J, Brendler T, Jaenicke C. PDR for Herbal Medicines. 1st ed. Montvale, NJ: Medical Economics Company, Inc., 1998.
Hebel SK, ed. Drug Facts and Comparisons. 52nd ed. St. Louis: Facts and Comparisons, 1998.
Tyrey L. Delta 9-Tetrahydrocannabinol: a potent inhibitor of episodic luteinizing hormone secretion. J Pharmacol Exp Ther 1980;213:306-8. DOI
Briggs GB, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1998.
Marinol Prescribing Information. Solvay Pharmaceuticals, Rev March 2008. Available at: http://www.solvaypharmaceuticals-us.com/static/wma/pdf/1/3/2/5/0/004InsertText500012RevMar2008.pdf (Accessed 2 July 2009).
Yamreudeewong W, Wong HK, Brausch LM, Pulley KR. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009;43:1347-53. PubMed
Pellinen, P., Honkakoski, P., Stenback, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M. A., and Pasanen, M. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur.J Pharmacol 1-3-1994;2 PubMed
Johnson, E. M. Substance abuse and women's health. Public Health Rep. 1987;102(4 Suppl):42-48.
Astley, S. J. and Little, R. E. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol.Teratol. 1990;12(2):161-168. PubMed
Levy, R., Schurr, A., Nathan, I., Dvilanski, A., and Livne, A. Impairment of ADP-induced platelet aggregation by hashish components. Thromb.Haemost. 12-31-1976;36(3):634-640. DOI
Sheweita, S. A. Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. Toxicology 9-30-2003;191(2-3):133-142. PubMed
Rog, D. J., Nurmikko, T. J., Friede, T., and Young, C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 9-27-2005;65(6):812-819. PubMed
Perras, C. Sativex for the management of multiple sclerosis symptoms. Issues Emerg.Health Technol. 2005;(72):1-4.
Zhu, H. J., Wang, J. S., Markowitz, J. S., Donovan, J. L., Gibson, B. B., Gefroh, H. A., and Devane, C. L. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp.Ther. 2006;317(2):850-857. PubMed
Holland, M. L., Panetta, J. A., Hoskins, J. M., Bebawy, M., Roufogalis, B. D., Allen, J. D., and Arnold, J. C. The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochem.Pharmacol 4-14-2006;71(8):1146-115 PubMed
Rog, D. J., Nurmikko, T. J., and Young, C. A. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-2079.
Reece, A. S. Chronic toxicology of cannabis. Clin Toxicol.(Phila) 2009;47(6):517-524. PubMed
Lynch, M. E. and Campbell, F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br.J.Clin.Pharmacol. 2011;72(5):735-744. PubMed
Li, M. C., Brady, J. E., DiMaggio, C. J., Lusardi, A. R., Tzong, K. Y., and Li, G. Marijuana use and motor vehicle crashes. Epidemiol.Rev. 2012;34(1):65-72. PubMed
Richards, B. L., Whittle, S. L., and Buchbinder, R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane.Database.Syst.Rev. 2012;1:CD008921. PubMed
Asbridge, M., Hayden, J. A., and Cartwright, J. L. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536. PubMed
Formukong, E. A., Evans, A. T., and Evans, F. J. The inhibitory effects of cannabinoids, the active constituents of Cannabis sativa L. on human and rabbit platelet aggregation. J.Pharm.Pharmacol. 1989;41(10):705-709.
Hollister, L. E. Interactions of cannabis with other drugs in man. NIDA Res.Monogr 1986;68:110-116. DOI
Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product--Colorado, March 2014. MMWR Morb Mortal Wkly Rep. 2015;64(28):771-2. PubMed
Huson HB, Granados TM, Rasko Y. Surgical considerations of marijuana use in elective procedures. Heliyon. 2018;4(9):e00779. PubMed
Goyal H, Awad HH, Ghali JK. Role of cannabis in cardiovascular disorders. J Thorac Dis. 2017;9(7):2079-2092. PubMed
Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. PubMed
Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 2015;313(24):2456-73. PubMed
Shere A, Goyal H. Cannabis can augment thrombolytic properties of rtPA: Intracranial hemorrhage in a heavy cannabis user. Am J Emerg Med. 2017;35(12):1988.e1-1988.e2. PubMed
Duran M, Pérez E, Abanades S, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol. 2010;70(5):656-63. PubMed
Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. PubMed
Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Pottegård A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol. 2019;124(1):28-31. PubMed
Product information for Marinol. AbbVie. North Chicago, IL 60064. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
Corsi DJ, Walsh L, Weiss D, et al. Association Between Self-reported Prenatal Cannabis Use and Maternal, Perinatal, and Neonatal Outcomes. JAMA. 2019 Jul 9;322(2):145-152. PubMed
Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2019 Nov 1;2(11):e1916318. PubMed
Rodriguez CE, Sheeder J, Allshouse AA, et al. Marijuana use in young mothers and adverse pregnancy outcomes: a retrospective cohort study. BJOG. 2019 Nov;126(12):1491-1497. PubMed
Smid MC. Marijuana use among young pregnant women: more common and more harmful than we think. BJOG. 2019 Nov;126(12):1498. PubMed
Brar BK, Patil PS, Jackson DN, Gardner MO, Alexander JM, Doyle NM. Effect of intrauterine marijuana exposure on fetal growth patterns and placental vascular resistance. J Matern Fetal Neonatal Med. 2019 Nov 11:1-5. PubMed
Budney AJ, Roffman R, Stephens R, Walker D. Marijuana dependence and its treatment. Addict Sci Clin Pract. 2007;4(1):4-16. PubMed
Zehra A, Burns J, Liu CK, et al. Cannabis Addiction and the Brain: a Review. J Neuroimmune Pharmacol. 2018;13(4):438-52. PubMed
Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(4):e202370. PubMed
Santaella-Tenorio J, Wheeler-Martin K, DiMaggio CJ, et al. Association of Recreational Cannabis Laws in Colorado and Washington State With Changes in Traffic Fatalities, 2005-2017. JAMA Intern Med. 2020. PubMed
Kloft L, Otgaar H, Blokland A, Garbaciak A, Monds LA, Ramaekers JG. False memory formation in cannabis users: a field study. Psychopharmacology (Berl). 2019;236(12):3439-3450. PubMed
Rosekind MR, Ehsani JP, Michael JP. Reducing Impaired Driving Fatalities: Data Need to Drive Testing, Enforcement, and Policy. JAMA Intern Med. 2020. PubMed
Kamer RS, Warshafsky S, Kamer GC. Change in Traffic Fatality Rates in the First 4 States to Legalize Recreational Marijuana. JAMA Intern Med. 2020. PubMed
Paul SP, Hatoum AS, Fine JD, et al. Associations between prenatal cannabis exposure and childhood outcomes: results from the ABCD Study. JAMA Psychiatry. 2020;e202902. PubMed
Monte AA, K Shelton SK, Mills E., Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med. 2019 Apr 16;170(8):531-537. PubMed
Arkell TR, Vinckenbosch F, Kevin RC, Theunissen EL, McGregor IS, Ramaekers JG. Effect of Cannabidiol and ?9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. JAMA. 2020;324(21):2177-2186.
Brown GW, Bellnier TJ, Janda M, Miskowitz K. ?-9-tetrahydrocannabinol dose increase leads to warfarin drug interaction and elevated INR. J Am Pharm Assoc (2003). 2021;61(1):e57-e60. PubMed
Cole TB, Saitz R. Cannabis and Impaired Driving. JAMA. 2020;324(21):2163-2164. PubMed
Corsi DJ, Donelle J, Sucha E, et al. Maternal cannabis use in pregnancy and child neurodevelopmental outcomes. Nat Med. 2020;26(10):1536-1540. PubMed
Grzeskowiak LE, Grieger JA, Andraweera P, et al. The deleterious effects of cannabis during pregnancy on neonatal outcomes. Med J Aust. 2020;212(11):519-524. PubMed
Tournier N, Lucie Chevillard L, Megarbane B, et al. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010;13(7):905-15. PubMed
Arnold JC, Hone P, Holland ML, Allen JD. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep. 2012;64(3):751-7. PubMed
Wymore EM, Palmer C, Wang GS, et al. Persistence of ?-9-Tetrahydrocannabinol in Human Breast Milk JAMA Pediatr. 2021. doi: 10.1001/jamapediatrics.2020.6098. PubMed
Velayudhan L, McGoohan K, Bhattacharyya S. Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis. PLoS Med. 2021;18(3):e1003524. PubMed
Mullins MF. Cannabis dabbing: An emerging trend. Nursing. 2021;51(5):46-50.
Kimura T, Takaya M, Usami N, Watanabe K, Yamamoto I. ?9-Tetrahydrocannabinol, a major marijuana component, enhances the anesthetic effect of pentobarbital through the CB1 receptor. Forensic Toxicol. 2019;37(1):207-214. DOI
Busse JW, Vankrunkelsven P, Zeng L, et al. Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ 2021;374:n2040. PubMed
Marchand G, Masoud AT, Govindan M, et al. Birth Outcomes of Neonates Exposed to Marijuana in Utero: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5(1):e2145653. PubMed
Maharaj N, Swarath S, Seecheran R, Seecheran V, Seecheran NA. Suspected cannabis vaping-induced pericardial effusion. J Investig Med High Impact Case Rep 2022;10:23247096221140251. PubMed
Idris I, Diez JR, Assoku BA, Beker S. Accidental ingestion of tetrahydrocannabinol-laced gummies causing bradycardia and first-degree atrioventricular block in a pediatric patient: A case report. Cureus 2022;14(7):e26826. PubMed
Senderovich H, Waicus S. A case report on cannabinoid hyperemesis syndrome in palliative care: How good intentions can go wrong. Oncol Res Treat 2022;45(7-8):438-443. PubMed
Englund A, Oliver D, Chesney E, et al. Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios. Neuropsychopharmacology 2022. PubMed
Zubcevic K, Petersen M, Bach FW, et al. Oral capsules of tetra-hydro-cannabinol (THC), cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment. Eur J Pain 2022.
Murray CH, Glazer JE, Lee R, Nusslock R, de Wit H. ?9-THC reduces reward-related brain activity in healthy adults. Psychopharmacology (Berl) 2022;239(9):2829-2840. PubMed
Hutten NRPW, Arkell TR, Vinckenbosch F, et al. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis. Psychopharmacology (Berl) 2022;239(11):3731-374 PubMed
Pisani S, McGoohan K, Velayudhan L, Bhattacharyya S. Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies. Drugs Aging 2021;38(10):887-910. PubMed
Highlights of prescribing information. MARINOL (dronabinol) capsules, for oral use, CIII. August 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf. Accessed April 10, 2023.
Cesamet (nabilone) capsules for oral administration. May 2006. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed April 10, 2023.
Moussa MK, Hall MAK, Akwe J. Cannabis-induced acute encephalopathy in a 94-year-old woman due to family administration of cannabidiol (CBD) products: A case report. Cureus 2023;15(4):e37927.
Zamarripa CA, Spindle TR, Surujunarain R, et al. Assessment of orally administered ?9-tetrahydrocannabinol when coadministered with cannabidiol on ?9-tetrahydrocannabinol pharmacokinetics and pharmacodynamics in healthy adults: A randomized clinical trial PubMed
van Dam CJ, van der Schrier R, van Velzen M, et al. Inhaled Delta(9)-tetrahydrocannabinol does not enhance oxycodone-induced respiratory depression: randomised controlled trial in healthy volunteers. Br J Anaesth 2023;130(4):485-493.
Treyer A, Reinhardt JK, Eigenmann DE, Oufir M, Hamburger M. Phytochemical comparison of medicinal cannabis extracts and study of their CYP-mediated interactions with coumarinic oral anticoagulants. Med Cannabis Cannabinoids. 2023;6(1):21-31. PubMed
Patel PA, Sanborn E, Then R, Williams DM. Recurrent Reversible Cerebral Vasoconstriction Syndrome: A Report of Two Cases. Cureus 2023;15(8):e42992. PubMed
Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. Clin Pharmacol Ther 2023.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Taking Delta-9-tetrahydrocannabinol (thc) and Rasagiline Together: Common Questions

Is it safe to take Delta-9-tetrahydrocannabinol (thc) with Rasagiline?

We do not list a known interaction between Delta-9-tetrahydrocannabinol (thc) and Rasagiline. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.

Do Delta-9-tetrahydrocannabinol (thc) and Rasagiline have any of the same side effects?

Yes — our sources link each of them separately to 10 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.

How was the Delta-9-tetrahydrocannabinol (thc) and Rasagiline combination checked?

Interactions in our licensed database are recorded against drug classes. Rasagiline is filed under 8 classifications, and Delta-9-tetrahydrocannabinol (thc) has documented interactions with 16 drug classes — none of Rasagiline's classifications are among them. A medication can belong to classes beyond those recorded in our dataset, so this describes how the check was run rather than guaranteeing safety.

Does Delta-9-tetrahydrocannabinol (thc) interact with any other medications?

Yes. Delta-9-tetrahydrocannabinol (thc) has 1,098 documented drug interactions in our database — Rasagiline is simply not one of them. If you take anything else, it is worth checking each one; they are all listed on this page.

Does Rasagiline interact with any supplements?

Yes. Rasagiline has documented interactions with 173 supplements in our database — Delta-9-tetrahydrocannabinol (thc) is not one of them. The Rasagiline interaction page linked on this page lists every one, ranked by severity.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Delta-9-tetrahydrocannabinol (thc) monograph Uses, safety profile, and every drug interaction in one place Rasagiline drug information The full plain-English guide to this medication Rasagiline supplement interactions Every supplement checked against Rasagiline, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 76 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Rasagiline and Delta-9-tetrahydrocannabinol (thc)?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.